Decoy Therapeutics (DCOY) director files Form 3 showing zero insider holdings
Rhea-AI Filing Summary
Decoy Therapeutics Inc. director Patricia G. Gauthier filed an initial insider ownership report indicating that she does not beneficially own any securities of the company. No equity or derivative positions are disclosed and no transactions are reported.
The filing also notes that an Exhibit 24 Power of Attorney is attached, authorizing representation for Section 16 reporting matters.
Positive
- None.
Negative
- None.
Key Terms
beneficially owned, Power of Attorney, Section 16
3 terms
beneficially owned regulatory
"Remarks state that no securities are beneficially owned."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Power of Attorney regulatory
"Exhibit 24, Power of Attorney, is attached."
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
Section 16 regulatory
"authorizing representation for Section 16 reporting matters"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Decoy Therapeutics (DCOY) disclose in this Form 3 filing?
Decoy Therapeutics reports that director Patricia G. Gauthier currently beneficially owns no securities of the company. The filing lists no holdings, no transactions, and attaches a Power of Attorney for Section 16 reporting.
Who is the reporting person in Decoy Therapeutics (DCOY) Form 3?
The reporting person is Patricia G. Gauthier, identified as a director of Decoy Therapeutics Inc. She reports no beneficial ownership of company securities in this initial statement of beneficial ownership of securities.
Are there any insider transactions reported for Decoy Therapeutics (DCOY) in this Form 3?
No transactions are reported. The Form 3 serves as an initial ownership report only and shows zero reported buys, sells, or derivative exercises, consistent with the statement that no securities are beneficially owned.
What is the significance of the Power of Attorney in the Decoy Therapeutics (DCOY) Form 3?
The filing notes that Exhibit 24, Power of Attorney, is attached. This authorizes a representative to sign and file Section 16 ownership reports on behalf of Patricia G. Gauthier, facilitating ongoing compliance with insider reporting rules.